- Aug 24 2016
PDS Announces Agreement with FDA on Phase 2 Clinical Path for PDS0101
August 2016—PDS has met with the FDA to discuss the recent results obtained in the company’s Phase I/IIA clinical study of PDS0101. The study projects a uniquely strong safety profile for PDS0101 as well as superior disease-specific T-cell response. PDS0101 is being developed to treat debilitating cancers caused by HPV infection including anal, cervical, vaginal, vulvar and head, and neck cancers.